Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC

被引：0
|
作者：
Simpson, Iain [1 ]
Anderton, Mark J. [1 ]
Andrews, David M. [1 ]
Breed, Jason [1 ]
Davies, Emma [1 ]
Debreczeni, Judit E. [1 ]
Flemington, Vikki [1 ]
Gibbons, Francis D. [2 ]
Graham, Mark A. [1 ]
Hopcroft, Philip [1 ]
Howard, Tina [1 ]
Hudson, Julian [1 ]
Jones, Clifford D. [1 ]
Jones, Christopher [1 ]
Lindsay, Nicola [1 ]
Pease, J. Elizabeth [1 ]
Rawlins, Philip [1 ]
Roberts, Karen [1 ]
Swallow, Steve [1 ]
St-Gallay, Steve [1 ]
Tonge, Michael E. [1 ]
Ward, Richard A. [1 ]
机构：
[1] AstraZeneca, Cambridge, England
[2] AstraZeneca, Boston, MA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1647
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
    Munck, J.
    Berdini, V.
    Courtin, A.
    East, C.
    Heightman, T.
    Hindley, C.
    Kucia-Tran, J.
    Lyons, J.
    Martins, V.
    Muench, S.
    Murray, C.
    Norton, D.
    O'Reilly, M.
    Reader, M.
    Rees, D.
    Rich, S.
    Thompson, N.
    Wilsher, N.
    Woolford, A.
    Wallis, N.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S53 - S53
  • [42] Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC)
    Wu, Wenjuan
    Bhagwat, Shripad V.
    King, Constance
    Pratt, Susan
    Gong, Xueqian
    Stewart, Julie
    Jones, Bonita
    Flack, Robert
    Beckman, Richard
    Falcon, Beverly
    Manro, Jason
    McMillen, William T.
    Tiu, Ramon V.
    Peng, Sheng-Bin
    Reinhard, Christoph
    Joseph, Sajan
    Buchanan, Sean
    CANCER RESEARCH, 2017, 77
  • [43] Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
    Wu, Wenjuan
    Bhagwat, Shripad
    Kindler, Lisa
    McMillen, William
    Joseph, Sajan
    Buchanan, Sean
    Reinhard, Christoph
    Tiu, Ramon V.
    Peng, Sheng-Bin
    CANCER RESEARCH, 2019, 79 (13)
  • [44] Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R)
    Degorce, Sebastien L.
    Boyd, Scott
    Curwen, Jon O.
    Ducray, Richard
    Halsall, Christopher T.
    Jones, Clifford D.
    Lach, Franck
    Lenz, Eva M.
    Pass, Martin
    Pass, Sarah
    Trigwell, Catherine
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (10) : 4859 - 4866
  • [45] OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models
    Libouban, Marion
    Jovcehva, Eleonora
    De lange, Desiree
    Janssens, Boudewijn
    Verhulst, Tinne
    Ogata, Souichi
    Wroblowski, Berthold
    Mevellec, Laurence
    Lu, Tianbao
    Clack, Glen
    Perera, Timothy
    CANCER RESEARCH, 2018, 78 (13)
  • [46] RP12146, a novel, selective, and potent small molecule inhibitor of PARP 1/2, synergizes with SOC therapy in preclinical models of solid tumors
    Viswanadha, S.
    Eleswarapu, S.
    Karnam, K.
    Vakkalanka, S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S33 - S33
  • [47] AZD4547, a potent and selective inhibitor of FGF-receptor tyrosine kinases 1, 2 and 3, inhibits the growth of FGF-receptor 2 driven gastric cancer models in vitro and in vivo
    Xie, Liang
    Su, Xinying
    Zhang, David
    Tang, Lily
    Xu, Jessie
    Wang, Maggie
    Yin, Lucy
    Zhang, Jingchuan
    Ye, Katherine
    Wang, Zengquan
    Kilgour, Elaine
    Ji, Qunsheng
    CANCER RESEARCH, 2011, 71
  • [48] FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
    Subbiah, Vivek
    Barve, Minal
    Iannotti, Nicholas O.
    Gutierrez, Martin
    Smith, David C.
    Roychowdhury, Sameek
    Papadopoulos, Kyriakos P.
    Mettu, Niharika
    Edenfield, William J.
    Morgensztern, Daniel
    Feliz, Luis
    Lihou, Christine
    Zhen, Huiling
    Saleh, Mansoor
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [49] eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
    Webster, Kevin R.
    Goel, Vikas K.
    Hung, Ivy N. J.
    Parker, Gregory S.
    Staunton, Jocelyn
    Neal, Melissa
    Molter, Jolene
    Chiang, Gary G.
    Jessen, Katti A.
    Wegerski, Christopher J.
    Sperry, Samuel
    Huang, Vera
    Chen, Joan
    Thompson, Peggy A.
    Appleman, James R.
    Webber, Stephen E.
    Sprengeler, Paul A.
    Reich, Siegfried H.
    BLOOD, 2015, 126 (23)
  • [50] Vertical inhibition of the MAPK pathway with D3S-002, a potent and selective ERK1/2 inhibitor, to improve anti-tumor activity of and overcome resistance to KRAS G12C inhibitors
    Zhang, Jing
    Lu, Jingtao
    Zheng, Zhiqiang
    Lu, Jiang
    Wang, Allison
    Wang, Jia
    Chen, Janet
    Rui, Haopeng
    Chen, Cheng
    Chen, Zhi Jian
    CANCER RESEARCH, 2023, 83 (07)
12345